Unlearn

Unlearn is a technology company that applies artificial intelligence to the design and conduct of clinical trials. Founded in 2017, it develops machine-learning methods - among them generative and unsupervised learning and predictive modelling - to build what it calls Digital Twins: AI-generated forecasts of the outcomes individual trial participants would be expected to experience. These forecasts allow sponsors to run studies with smaller control groups and shorter timelines than conventional designs permit.

The company's flagship product, Digital Twins, is aimed at biopharma, pharmaceutical and clinical-development customers seeking more robust and efficient trials. Unlearn positions its work as an application of computation to medicine rather than to wet-lab research; its stated ambition is to reduce trial-and-error in clinical development.

Unlearn describes itself as a team of scientists, engineers and builders working on problems in AI in medicine, and characterises its culture as ambitious, iterative and unsatisfied with existing practice in clinical development. Its name derives from the phrase "unsupervised learning". Further company information is available at unlearn.ai.